Eli Lilly Isn’t Telling Us About Their Future Obesity Drugs
Does Eli Lilly already have the solve for obesity? In this episode of On the Pen — the Weekly Dose Podcast, host Dave Knapp breaks down a stunning comment from Lilly's Chief Scientific Officer Daniel ...
2 Kesä 20min
Retatrutide, Multi Agonist Obesity Drugs, and the PBM Access War
https://linktr.ee/manonthemounjaro
26 Touko 30min
The Next Two Weeks in GLP1 Are Huge, Here's Why
http://www.otplinks.com
12 Touko 1h 7min
He Took Retatrutide 40mg and Proved a Point
This episode examines a serious case involving retatrutide, where an individual experienced an overdose due to improper medication administration. We discuss the critical importance of medication safe...
5 Touko 36min
Eli Lilly Earnings Call Recap: Q1 2026
We just got done listening to the quarter one, 2026 Eli Lilly earnings call. There was a lot of information to get into, whether you're interested in retatrutide, eloralintide, or Foundayo, and all of...
30 Huhti 25min
SURVODUTIDE Phase 3 Data: Why Weight Loss Isn't The Whole Story
https://www.otplinks.comA new GLP-1 and glucagon agonist dropped data that was supposed to rival retatrutide, just without the GIP, and on the surface the results look solid. But that is not the real ...
28 Huhti 18min
BPI STOPS TIRZEPATIDE Production, Second Major Pharmacy Out!
Major disruption hits the GLP-1 landscape as another large 503B compounding pharmacy halts production of semaglutide and tirzepatide. In this episode, we unpack what’s driving the FDA’s increased enfo...
23 Huhti 40min
